VANDA PHARMACEUTICALS INC (VNDA)
US9216591084 - Common Stock
We assign a fundamental rating of 4 out of 10 to VNDA. VNDA was compared to 565 industry peers in the Biotechnology industry. VNDA is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. VNDA has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year VNDA has reported negative net income.
VNDA had a negative operating cash flow in the past year.
Each year in the past 5 years VNDA has been profitable.
VNDA had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
VNDA has a better Return On Assets (-2.54%) than 90.39% of its industry peers.
VNDA has a better Return On Equity (-3.03%) than 92.53% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.54% | ||
| ROE | -3.03% | ||
| ROIC | N/A |
ROA(3y)2.32%
ROA(5y)7.05%
ROE(3y)2.74%
ROE(5y)8.3%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
VNDA's Profit Margin has declined in the last couple of years.
The Gross Margin of VNDA (93.62%) is better than 95.02% of its industry peers.
In the last couple of years the Gross Margin of VNDA has remained more or less at the same level.
VNDA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 93.62% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-48.23%
PM growth 5Y-36.93%
GM growth 3Y0.64%
GM growth 5Y0.65%
2. Health
2.1 Basic Checks
VNDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VNDA has been increased compared to 1 year ago.
The number of shares outstanding for VNDA has been increased compared to 5 years ago.
There is no outstanding debt for VNDA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
VNDA has an Altman-Z score of 1.95. This is not the best score and indicates that VNDA is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of VNDA (1.95) is better than 71.00% of its industry peers.
VNDA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.95 |
ROIC/WACCN/A
WACC10.93%
2.3 Liquidity
A Current Ratio of 4.85 indicates that VNDA has no problem at all paying its short term obligations.
VNDA has a Current ratio (4.85) which is in line with its industry peers.
A Quick Ratio of 4.84 indicates that VNDA has no problem at all paying its short term obligations.
VNDA has a Quick ratio of 4.84. This is comparable to the rest of the industry: VNDA outperforms 54.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.85 | ||
| Quick Ratio | 4.84 |
3. Growth
3.1 Past
The earnings per share for VNDA have decreased strongly by -233.33% in the last year.
Measured over the past years, VNDA shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -36.12% on average per year.
The Revenue has decreased by -9.91% in the past year.
The Revenue has been decreasing by -0.05% on average over the past years.
EPS 1Y (TTM)-233.33%
EPS 3Y-51.19%
EPS 5Y-36.12%
EPS Q2Q%N/A
Revenue 1Y (TTM)-9.91%
Revenue growth 3Y-8.1%
Revenue growth 5Y-0.05%
Sales Q2Q%22.76%
3.2 Future
Based on estimates for the next years, VNDA will show a very strong growth in Earnings Per Share. The EPS will grow by 174.15% on average per year.
VNDA is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.50% yearly.
EPS Next Y-752.8%
EPS Next 2Y103.66%
EPS Next 3Y174.15%
EPS Next 5YN/A
Revenue Next Year8.16%
Revenue Next 2Y24.3%
Revenue Next 3Y21.37%
Revenue Next 5Y5.5%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for VNDA. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 23.29, which indicates a rather expensive current valuation of VNDA.
Based on the Price/Forward Earnings ratio, VNDA is valued cheaper than 94.13% of the companies in the same industry.
VNDA's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 23.99.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 23.29 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
VNDA's earnings are expected to grow with 174.15% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y103.66%
EPS Next 3Y174.15%
5. Dividend
5.1 Amount
VNDA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VANDA PHARMACEUTICALS INC
NASDAQ:VNDA (12/24/2024, 7:44:28 PM)
After market: 4.83 0 (0%)4.83
+0.15 (+3.21%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners76.88%
Inst Owner Change1.64%
Ins Owners3.07%
Ins Owner Change-0.19%
Market Cap281.64M
Analysts80
Price Target10.64 (120.29%)
Short Float %5.48%
Short Ratio4.42
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)54.31%
Min EPS beat(2)45.98%
Max EPS beat(2)62.65%
EPS beat(4)3
Avg EPS beat(4)-18.05%
Min EPS beat(4)-237.25%
Max EPS beat(4)62.65%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.78%
Min Revenue beat(2)-4.96%
Max Revenue beat(2)3.39%
Revenue beat(4)2
Avg Revenue beat(4)3.58%
Min Revenue beat(4)-4.96%
Max Revenue beat(4)19.95%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)29.21%
PT rev (3m)29.21%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-6.67%
EPS NY rev (1m)9.43%
EPS NY rev (3m)34.69%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.46%
Revenue NY rev (1m)0.44%
Revenue NY rev (3m)-1.03%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 23.29 | ||
| P/S | 1.48 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.52 | ||
| P/tB | 0.66 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.28
EYN/A
EPS(NY)0.21
Fwd EY4.29%
FCF(TTM)-0.31
FCFYN/A
OCF(TTM)-0.3
OCFYN/A
SpS3.27
BVpS9.28
TBVpS7.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.54% | ||
| ROE | -3.03% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 93.62% | ||
| FCFM | N/A |
ROA(3y)2.32%
ROA(5y)7.05%
ROE(3y)2.74%
ROE(5y)8.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-48.23%
PM growth 5Y-36.93%
GM growth 3Y0.64%
GM growth 5Y0.65%
F-Score2
Asset Turnover0.3
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 7.59% | ||
| Cap/Sales | 0.29% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.85 | ||
| Quick Ratio | 4.84 | ||
| Altman-Z | 1.95 |
F-Score2
WACC10.93%
ROIC/WACCN/A
Cap/Depr(3y)19.78%
Cap/Depr(5y)31.18%
Cap/Sales(3y)0.23%
Cap/Sales(5y)0.37%
Profit Quality(3y)394.44%
Profit Quality(5y)287.35%
High Growth Momentum
Growth
EPS 1Y (TTM)-233.33%
EPS 3Y-51.19%
EPS 5Y-36.12%
EPS Q2Q%N/A
EPS Next Y-752.8%
EPS Next 2Y103.66%
EPS Next 3Y174.15%
EPS Next 5YN/A
Revenue 1Y (TTM)-9.91%
Revenue growth 3Y-8.1%
Revenue growth 5Y-0.05%
Sales Q2Q%22.76%
Revenue Next Year8.16%
Revenue Next 2Y24.3%
Revenue Next 3Y21.37%
Revenue Next 5Y5.5%
EBIT growth 1Y-15514.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-9.78%
EBIT Next 3Y38.33%
EBIT Next 5YN/A
FCF growth 1Y-137.44%
FCF growth 3Y-37.14%
FCF growth 5Y21.97%
OCF growth 1Y-135.85%
OCF growth 3Y-37.25%
OCF growth 5Y-15.66%